FindTrial
Sign In

Aspin: Neurosurgical Aspirin Intervention Prognostic Study. Perioperative continuation versus discontinuation of aspirin in degenerative spinal surgery, a randomized controlled, noninferiority trial

Aspin: Neurosurgical Aspirin Intervention Prognostic Study. Perioperative continuation versus discontinuation of aspirin in degenerative spinal surgery, a randomized controlled, noninferiority trial - Aspin: Neurosurgical Aspirin Intervention Prognostic Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON54741
Enrollment
Unknown
Registered
2020-10-06
Start date
2022-01-25
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding stroke Bleeding and stroke.

Interventions

The intervention group will be continuing asprin peri-operatively.

Sponsors

Haaglanden Medisch Centrum (HMC)
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Elective spinal surgery Pre-operative use of aniplatelet drugs Pre-operative use of aspirin

Exclusion criteria

Exclusion criteria: Spinal oncology Staged surgeries lasting more than one day Patients with a pre-existing coagulopathy Patients using antithrombotic drugs or other platelet aggregation inhibitors than aspirin Patients with absolute contraindication for discontinuing aspirin (e.g. coronary stenting within 1 year) Patients aged under 18 Emergency surgical procedures Incompetence to decide, i.e. in case of severe cognitive impairment or psychiatric illness.

Design outcomes

Primary

MeasureTime frame
See study objectives.—

Secondary

MeasureTime frame
See study objectives.—

Countries

Netherlands

Contacts

Public ContactA Zian

Haaglanden Medisch Centrum (HMC)

secr.neurochirurgie@haaglandenmc.nl088 979 43 65

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)